ArticlePloS one2026
Bacterial profile and antibiotic susceptibility of bloodstream infections among infants, children, and adolescents undergoing treatment for acute leukemia.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPediatric patients with acute leukemia are at risk of bacteremia due to disease and treatment-related toxicities. Limited data exists on pathogen distribution across different pediatric age groups. This study aims to investigate the distribution of bacterial pathogens and their susceptibility patterns across infants, children, and adolescents undergoing treatment for acute leukemia.
methodsRetrospective cohort study that included pediatric patients with Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML) who had positive blood cultures between 01/01/2015-31/12/2024. Bacteremia was defined as the presence of bacterial microorganisms in the bloodstream, confirmed by one or more positive blood cultures with associated symptoms. Patients were categorized into three age groups: infants (≤1 year), children (>1 to <12 years), and adolescents (≥12 to ≤18 years). Collected data included demographics, leukemia disease risk (high, standard or low), treatment phase (induction, consolidation, maintenance, relapse, or palliative care), signs and symptoms and the causative pathogen along with its susceptibility and resistance testing. Descriptive statistics were used to summarize findings.
resultsA total of 308 bacteremia episodes among 160 patients were identified. Of these, 291 (94%) episodes occurred in ALL patients and 17 (6%) in AML patients. The median age was 5 years (IQR 3-11 years) with children, adolescents, and infants representing 78%, 21%, and 1%, respectively. A total of 330 bacterial isolates were identified. Isolates were most frequently recovered during consolidation (30%), induction (24%), and maintenance (23%) phases. Gram-positive organisms, particularly Staphylococcus spp. predominated across all treatment phases and age groups. Whereas a higher proportion of Gram-negative organisms - including Escherichia coli, Klebsiella spp., and Pseudomonas spp. - were observed among adolescents and patients in high-risk groups. Antimicrobial resistance was confined to Escherichia coli and Klebsiella spp. exhibiting Extended-Spectrum β-lactamase and Carbapenem-Resistant Enterobacterales phenotypes across the cohort.
conclusionsIn this single-center descriptive study, bacteremia episodes and bacterial isolates showed descriptive differences across age groups, treatment phases, and leukemia risk categories. These findings support continued local infection surveillance. Larger multicenter studies with sufficient subgroup representation are needed to determine whether age- or phase-specific empiric therapy strategies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.